Equity Method of Accounting for Common Stock of Oncocyte, at Fair Value (Tables)

12 Months Ended

Dec. 31, 2018

OncoCyte Corporation [Member]

Schedule of Equity Method Investments [Line Items]

Schedule of Condensed Results of Operations and Balance sheet Information

The condensed results of operations and condensed balance sheet information of OncoCyte are summarized below (in thousands):

	For the Period January 1, 2017 through February 16, 2017 (1)
Condensed Statement of Operations (1)
Research and development expense	$	798
General and administrative expense		377
Sales and marketing expense		213
Loss from operations		(1,388)
Net loss	$	(1,392)

(1) OncoCyte’s condensed results of operations for the period from January 1, 2017 through February 16, 2017, the date immediately preceding the OncoCyte Deconsolidation, for the year ended December 31, 2017, shown in the table below, is included in the consolidated results of operations of BioTime, after intercompany eliminations, as applicable.

The following table summarizes OncoCyte results of operations for the full years ended December 31, 2018 and 2017 (in thousands).

	Year Ended December 31,
Condensed Statements of Operations	2018		2017
Research and development expense	$	6,506	$	7,174
General and administrative expense		6,153		9,232
Sales and marketing expense		1,681		2,443
Loss from operations		(14,340)		(18,849)
Net loss	$	(14,890)	$	(19,375)

	December 31,
Condensed Balance Sheet information (1)	2018		2017
Current assets	$	8,642	$	8,528
Noncurrent assets		876		1,688
	$	9,518	$	10,216
Current liabilities	$	4,698	$	4,454
Noncurrent liabilities		534		1,359
Stockholders’ equity		4,286		4,403
	$	9,518	$	10,216

(1) The condensed balance sheet information of OncoCyte as of December 31, 2018 and 2017, is provided for informational and comparative purposes only. OncoCyte was not included in BioTime’s consolidated balance sheet as of December 31, 2018 and 2017 due to the OncoCyte Deconsolidation on February 17, 2017.